NRX Pharmaceuticals, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by NRX Pharmaceuticals, Inc. on March 28, 2024. The filing reports a material corporate action involving a 1-for-10 reverse stock split of the Company's common stock, effective April 1, 2024.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the structural change to the Company's capitalization.
Material Changes
- Reverse Stock Split: A 1-for-10 reverse stock split was approved and filed with the Delaware Secretary of State.
- Share Count Reduction: The number of issued and outstanding shares will decrease from 95,699,780 to approximately 9,569,978 shares.
- Fractional Shares: No fractional shares will be issued; any fractional entitlements will be rounded up to the nearest whole share.
- Ownership Impact: The split will not affect any stockholder's percentage ownership interest, except for minor adjustments due to the rounding of fractional shares.
- Trading Details: Common stock will begin trading on a split-adjusted basis on The Nasdaq Capital Market on April 2, 2024, under the symbol "NRXP" with a new CUSIP number (629444209).
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure regarding the treatment of fractional shares. The primary purpose is to disclose the amendment to the Articles of Incorporation.
Key Facts for Investor Verification
- Verify the new CUSIP number (629444209) for the post-split common stock.
- Confirm the effective trading date of April 2, 2024, on The Nasdaq Capital Market.
- Review the definitive proxy statement filed on March 11, 2024, for detailed terms of the special meeting.
- Check brokerage account statements to ensure fractional shares were rounded up correctly rather than sold for cash.